《中华眼科杂志》2006年12期 加入收藏    获取最新 
 ~(99)Tc~m-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用
 段炼;李险峰;陆克义;张承刚;胡光;刘建中;李思进
 　　目的研究99Tcm-奥曲肽眼眶显像在判断甲状腺相关眼病(TAO)患者眼部炎性反应活动度中的临床价值。方法根据临床活动度评分(CAS)标准,将30例TAO患者分为活动组和非活动组,11例正常志愿者为对照组。所有对象行99Tcm-奥曲肽眼眶断层显像,并计算眼眶奥曲肽摄取比值(UR)。6例活动组患者于抗炎治疗后进行了二次显像。结果3组眼眶的奥曲肽UR均数分别为1·40±0·18、1·15±0·10及1·07±0·20,活动组与非活动组、对照组两两相比,差异均有统计学意义(均P<0·001);非活动组与对照组相比,差异无统计学意义(P>0·05)。所有TAO患者的UR与其CAS具有良好的相关性(rall=0·859,P<0·001)。对活动组患者的治疗前后UR比较,差异有统计学意义(t=4·39,P=0·007)。治疗前后CAS比较,差异有统计学意义(Z=-5·51,P<0·001),表明治疗后评分降低,治疗有效。结论99Tcm-奥曲肽眼眶显像可帮助临床医师判断TAO炎性反应活动度,为制订治疗方案提供依据,并可用于疗效评价。
【作者单位】：山西医科大学第一医院核医学科;山西医科大学第一医院核医学科;山西医科大学第一医院核医学科;山西医科大学第一医院核医学科;山西医科大学第一医院核医学科;山西医科大学第一医院核医学科;山西医科大学第一医院核医学科 030001太原;长治医学院附属和平医院核医学科;046000;030001太原;030001太原;030001太原;030001太原;030001太原;030001太原
【关键词】：格雷夫斯病;受体,生长抑素;放射性核素显像;奥曲肽;锝
【分类号】：R771.3
【DOI】：CNKI:ISSN:0412-4081.0.2006-12-007
【正文快照】：
　　甲状腺相关眼病(thyroid associatedophthalmopathy,TAO)是眼眶最常见的疾病之一,在国内外成年人眼眶疾病中均为第1位,约占20%[1]。目前国内外对此病的治疗基本趋于一致[2],如果眼部病变正处于炎性反应活动期,应及时给予糖皮质激素、生长抑素类似物或局部放射治疗等,可取得较为
 
 推荐 下载CAJ全文           下载PDF全文
 CAJViewer7.0阅读器支持所有CNKI文件格式，AdobeReader仅支持PDF格式
 Clinical application of orbital scintigraphy with ~(99)Tc~m-octreotide in patients with thyroid associated ophthalmopathy
 DUAN Lian;LI Xian-feng;LU Ke-yi;ZHANG Cheng-gang;HU Guang;LIU Jian-zhong;LI Si-jin. Department of Nuclear Medicine;the First Hospital of Shanxi Medical University;Taiyuan 030001;China
 　Objective To analyze the feasibility of estimation of thyroid associated ophthalmopathy (TAO) activity with orbital scintigraphy using ~ 99 Tc~m-octreotide. Methods There were 30 cases of TAO and 11 volunteers without eye disease or thyroid disease (control group, CG). Some examinations were performed before treatment. Based on the clinical activity score (CAS), all TAO patients were divided into 2 groups, active group (AG) and inactive group (IAG). Orbit scintigraphy study of orbit was completed within 1.0-1.5 h after intravenous injection of 740 MBq ~ 99 Tc~m-octreotide. The best transverse slice for displaying eye was selected to take semi quantitative analysis. The regions of interest of right orbit (R), left orbit (L) and occipital (O) were selected. The uptake ratios (UR) were calculated in (R+L)/2O. And then, all active patients accepted immunosuppressive therapy with prednisone after ~ 131 I therapy. Six patients performed octreotide scan twice. The statistical analyses included ANOVA, Spearman regression analysis and paired t-test using SPSS 10.0. Results ~ 99 Tc~m-octreotide biokinetics showed a rapid blood clearance through urinary system. The orbit appeared as a “cold area” in CG. The orbit uptake of AG had a visual orbital accumulation of ~ 99 Tc~m-octreotide, but little in IAG (UR_ act =1.40±0.18, UR_ inact =1.15±0.10, UR_ contr =1.07±0.20). There was a significant difference between IAG and AG of UR (P<0.001). A statistically significant correlation was found between CAS and UR (UR_ all vs. CAS_ all , r= 0.859,P<0.001). After 12 weeks treatment with prednisone, the signs and symptoms of inflammation had lightened, UR pretreat vs. UR posttreat(t= 4.39, P=0.007);CAS pretreat vs. CAS posttreat(Z=-5.51,P<0.001). Conclusions Orbital scintigraphy with ~ 99 Tc~m-octreotide is a method for judging activity of inflammation in TAO based on the distribution of somatostatin receptors, lymphocyte infiltration and fibroblast activating in retrobulbar tissue. There is a good correlation between CAS and UR. The scintigraphy can estimate activity of TAO and help to formulate therapy program and evaluate the therapeutic effects.
【Keyword】：Graves′ disease;Receptors, somatostatin;Radio nuclide imaging;Octreotide;Technetium
 【参考文献】 共（2）篇 
 中国期刊全文数据库找到 2 条
 
1段炼,李险峰,胡光,张承刚,李思进; ~(99)Tc~m-奥曲肽眼眶显像在甲状腺相关眼病中的初步应用 [J];山西医科大学学报; 2005年03期
2李玲,叶万忠,李建,陈侃,张春华,包建东; Graves眼病眶部生长抑素受体显像研究 [J];中华核医学杂志; 2005年03期
 【二级参考文献】 共（7）篇 
 中国期刊全文数据库找到 5 条
 
1胡蜀红; Graves眼病的发病机理 [J];国外医学.内分泌学分册; 2002年02期
2王坚,王扬天,邵加庆,王晓,杜宏; Graves眼病部分免疫抑制剂疗效探讨 [J];中华内科杂志; 2004年02期
3管昌田,梁正路,管玫,李云春; ~(99m)Tc-octre otide和~(111)In-DTPA-octre otide受体显像诊断肿瘤的比较研究 [J];肿瘤学杂志; 2001年05期
4管昌田,武洪文; ~(111)In-奥曲肽受体显像在肿瘤和Graves病中的应用 [J];中华核医学杂志; 1999年03期
5崔炯,王中心,杨芳; 血清白介素6及其可溶性受体水平与Graves眼病活动性 [J];中华内分泌代谢杂志; 2004年03期
 西文参考文献找到 2 条
 
1Chavis PS; Thyroid and eye [M];Curr Opin Ophthalmol; 2002年
2Kainz H, Bale R, Donnemiller E, et al; Image fusion analysis of 99 Tcm-HYNIC-Octreotide scintigraphy and CT/MRI in patients with thyroid-associated ophthalmopathy: the importance of the lacrimal gland [M];Eur J Nucl Med; 2003年
 【相似文献】 
 中国期刊全文数据库
 
1周晓红,罗清礼,夏瑞南; Graves眼病眼眶组织病理与IgA、IgE表达的研究 [J];中华眼科杂志; 1999年04期; 31-33
2刘燕强,赵强,伍昭龙,季青; 生长抑素及其受体在视网膜发育过程中的表达和意义 [J];中华眼科杂志; 2006年04期; 82-85
3唐莉,罗清礼,周晓红,夏瑞南; Graves眼病患者外周血细胞因子表达的研究 [J];中华眼科杂志; 2002年03期; 40-42
4段炼,李险峰,胡光,张承刚,李思进; ~(99)Tc~m-奥曲肽眼眶显像在甲状腺相关眼病中的初步应用 [J];山西医科大学学报; 2005年03期; 107-109
5段炼,李险峰,陆克义,张承刚,胡光,刘建中,李思进; ~(99)Tc~m-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用 [J];中华眼科杂志; 2006年12期; 17-21